StemRIM (TYO:4599)

Japan flag Japan · Delayed Price · Currency is JPY
307.00
-3.00 (-0.97%)
May 15, 2026, 3:30 PM JST
Market Cap19.43B +7.1%
Revenue (ttm)n/a
Net Income-1.81B
EPS-29.08
Shares Out62.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume255,400
Average Volume134,435
Open311.00
Previous Close310.00
Day's Range303.00 - 313.00
52-Week Range246.00 - 360.00
Beta0.94
RSI52.04
Earnings DateJun 10, 2026

About StemRIM

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene thera... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 45
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4599
Full Company Profile

Financial Performance

Financial Statements